Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Biosimilars start-up Epirus raises $36mm in its Series B round

Executive Summary

Epirus Biopharmaceuticals Inc. (biosimilar mAbs and therapeutic proteins) raised $36mm in a Series B financing led by new investor Livzon Mabpharm (a division of public Chinese biotech Livzon Pharmaceutical Group). Additional participants included new backers Adage Capital, Greenwoods Investment, Gibralt US Inc., Monashee Capital Partners LP, and an affiliate of Mousse Partners, along with returning investors TPG Biotech, Montreux Equity Partners, and 5AM Ventures. Leerink Partners LLC was the placement agent.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies